B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Nature Immunology

• Publication date

  2001-03-01

• Fields of study

  Biology

• Identifiers
  DOI 10.1038/85339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• LIGHT,a TNF-Like Molecule,Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogenic T Cell Response

  2001cited by this paper
• Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• LICOS, a primordial costimulatory ligand?

  2000cited by this paper
• Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor

  2000cited by this paper
• Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules.

  2000cited by this paper
• In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells.

  2000cited by this paper
• Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS.

  2000cited by this paper
• Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.

  2000cited by this paper
• Characterization of Human Inducible Costimulator Ligand Expression and Function1

  2000cited by this paper
• B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha.

  1999cited by this paper
• ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

  1999cited by this paper
• Structure and evolution of the extended B7 family.

  1999cited by this paper
• The central effectors of cell death in the immune system.

  1999cited by this paper
• T-cell co-stimulation through B7RP-1 and ICOS

  1999cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.

  1998cited by this paper
• Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts.

  1997cited by this paper
• Co-stimulation in T cell responses.

  1997cited by this paper
• CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301]

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• CD28 and apoptosis.

  1995cited by this paper
• Metalloproteinase-mediated release of human Fas ligand

  1995cited by this paper
• Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen.

  1994cited by this paper
• Extending the B7 (CD80) gene family

  1994cited by this paper
• The role of the CD28 receptor during T cell responses to antigen.

  1993cited by this paper
• The molecular cell biology of interferon-gamma and its receptor.

  1993cited by this paper
• Characterization of CTLA-4 structure and expression on human T cells.

  1993cited by this paper
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper
• Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes

  1992cited by this paper

• CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.

  2026cites this paper
• Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value

  2026cites this paper
• Development of a Novel Extracellular Vesicle‐Based Biomarker Approach for Pediatric High‐Grade Glioma

  2026cites this paper
• Does the B7-H3 Immune Checkpoint Have High Potential as a Therapeutic Target?

  2026cites this paper
• Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer

  2026cites this paper
• Low-affinity binding of anti-B7-H3 clone MJ18 to murine B7-H3 fails to induce tumor regression.

  2026cites this paper
• Shifting tides from non-targeted chemotherapy to targeted therapies and small RNA-based bio drugs: A changing paradigm in cancer therapy.

  2025cites this paper
• Immune checkpoint blockade for cancer therapy: current progress and perspectives

  2025cites this paper
• B7-H3: a promising target for immunotherapy in glioma

  2025cites this paper
• Establishment of iPSC-Derived MSCs Expressing hsa-miR-4662a-5p for Enhanced Immune Modulation in Graft-Versus-Host Disease (GVHD)

  2025cites this paper
• The challenges and progress of CAR-T cell therapy in the treatment of solid tumors

  2025cites this paper
• B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades

  2025cites this paper
• Exploiting B7-H3: Molecular Insights and Immunotherapeutic Strategies for Osteosarcoma

  2025cites this paper
• Adaptive Responses of Large Yellow Croaker Larimichthys crocea to Ocean Acidification: Integrative Analysis of Gill and Kidney Transcriptomics and Antioxidant Enzyme Activities

  2025cites this paper
• Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

  2025cites this paper
• Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics.

  2025cites this paper
• A fc-engineered NKG2D × B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes.

  2025cites this paper
• Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases

  2025cites this paper
• Research progress of B7-H3 in malignant tumors

  2025cites this paper
• Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families

  2025cites this paper
• Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications

  2025cites this paper
• Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers.

  2025cites this paper
• VSIG2 as a novel immunosuppressive ligand interacts with Nectin-2 to regulate T cell responses

  2025cites this paper
• B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature

  2025cites this paper
• SH3GL1 mediates B7-H3 recycling and enhances the immune escape in non-small cell lung cancer

  2025cites this paper
• Targeting B7-H3 in Cancer-Associated Fibroblasts Using Nanosystems Suppresses Anaplastic Thyroid Carcinoma Progression

  2025cites this paper
• Prognostic and Predictive Significance of B7-H3 and CD155 Expression in Gastric Cancer Patients

  2025cites this paper
• Diagnostic and Therapeutic Approach to Metachronous Splenic Metastases of Gastric Adenocarcinoma: Case Report and Literature Review

  2025cites this paper
• Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy

  2025cites this paper
• Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy

  2025cites this paper
• The current and emerging immunotherapy paradigm in small-cell lung cancer

  2025cites this paper
• An engineered nanosystem for reprogramming circulating malignant cells and the tumor-immune axis

  2025cites this paper
• An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer

  2025cites this paper
• A monoclonal antibody targeting B7-H3 in human embryonic stem cells exhibits anti-tumor activity in hepatocellular carcinoma xenografts

  2025cites this paper
• B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors

  2025cites this paper
• Advances in molecular pathology and therapy of non-small cell lung cancer

  2025cites this paper
• Identification of the B7-H3 Interaction Partners Using a Proximity Labeling Strategy

  2025cites this paper
• Tumor Vascular Normalization by B7-H3 Blockade Augments T Lymphocyte-Mediated Antitumor Immunity.

  2025cites this paper
• Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy

  2025cites this paper
• A novel cancer-associated lncRNA, LINC01123, participates in tumor progression, metabolism, immune escape, and resistance

  2025cites this paper
• B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer

  2025cites this paper
• Promotion of the invasion and metastasis of breast cancer by B7-H3 through CCR5High tumor-associated macrophages

  2025cites this paper
• Recent research progress and clinical status of immunotherapy for colorectal cancer.

  2025cites this paper
• B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature

  2025cites this paper
• Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer

  2025cites this paper
• Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates

  2025cites this paper
• Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside.

  2025cites this paper
• Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value.

  2025cites this paper
• Identification of c‐Met on Tumor Cells as a Novel Receptor for B7‐H3 Entails Implications for Cancer Cell Stemness and Targeted Therapy

  2025cites this paper
• Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide

  2025cites this paper
• Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies

  2025cites this paper
• Functional characterization and clinical significance of IGSF8 in pan-cancer: an integrated bioinformatic and experimental study

  2025cites this paper
• B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity.

  2025cites this paper
• PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer

  2025cites this paper
• The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms.

  2025cites this paper
• Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice

  2025cites this paper
• Patterns and trajectories of peripheral inflammatory cytokines, immune tolerance, and lymphocyte differentiation predict transition from acute to chronic low back pain in a sex- and age-specific manner.

  2025cites this paper
• Crosstalk between tumor-associated macrophages and the B7/CD28 family in immune checkpoint inhibitor-induced immunotherapy

  2025cites this paper
• Construction of a prognostic model for nasopharyngeal carcinoma based on serum exosomal circular RNAs and analysis of immune microenvironment

  2025cites this paper
• Multiplexed spatial imaging at the single-cell level reveals mutually exclusive expression of B7 family proteins.

  2024cites this paper
• CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research

  2024cites this paper
• Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape

  2024cites this paper
• CD276 is a promising biomarker for the prognosis of clear cell renal cell carcinoma

  2024cites this paper
• B7 homolog 3 in pancreatic cancer

  2024cites this paper
• Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives

  2024cites this paper
• Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer

  2024cites this paper
• An integrated pan-cancer assessment of prognosis, immune infiltration, and immunotherapy response for B7 family using multi-omics data.

  2024cites this paper
• Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

  2024cites this paper
• Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy

  2024cites this paper
• The Human Neonatal Skin Fibroblast, an Available Cell Source for Tissue Production and Transplantation, Exhibits Low Risk of Immunogenicity In Vitro

  2024cites this paper
• Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

  2024cites this paper
• Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia

  2024cites this paper
• The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma

  2024cites this paper
• Novel antibody-drug conjugates based on DXd-ADC technology.

  2024cites this paper
• Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections

  2024cites this paper
• Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression

  2024cites this paper
• LAG‐3 : recent developments in combinational therapies in cancer

  2024cites this paper
• Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

  2024cites this paper
• Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

  2024cites this paper
• Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma

  2024cites this paper
• Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.

  2024cites this paper
• B7-H3 Expression in Breast Cancer and Brain Metastasis

  2024cites this paper
• B7-H3 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target

  2024cites this paper
• Mapping spatial heterogeneity in gastric cancer microenvironment.

  2024cites this paper
• NR1D1‐transactivated lncRNA NUTM2A‐AS1 promotes chemoresistance and immune evasion in neuroblastoma via inhibiting B7‐H3 degradation

  2024cites this paper
• CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives

  2024cites this paper
• Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies

  2024cites this paper
• A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors

  2024cites this paper
• miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review

  2024cites this paper
• Treatment advances in high-grade gliomas

  2024cites this paper
• Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response

  2024cites this paper
• Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration

  2024cites this paper
• The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages

  2024cites this paper
• Immune Checkpoint Molecules and Maternal–Fetal Immunity

  2024cites this paper
• Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response

  2024cites this paper
• New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3

  2024influential citation
• Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

  2024cites this paper
• B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma

  2024cites this paper
• Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling

  2024cites this paper
• Tissue biomarkers of immune checkpoint inhibitor therapy

  2024cites this paper